Zacks Investment Research Lowers Ritter Pharmaceuticals (NASDAQ:RTTR) to Hold

Share on StockTwits

Zacks Investment Research cut shares of Ritter Pharmaceuticals (NASDAQ:RTTR) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning, Zacks.com reports.

According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “

Separately, ValuEngine downgraded Zumiez from a hold rating to a sell rating in a research report on Tuesday, July 2nd.

NASDAQ:RTTR opened at $0.99 on Wednesday. The stock’s fifty day moving average is $0.96. Ritter Pharmaceuticals has a 1 year low of $0.47 and a 1 year high of $2.56.

Ritter Pharmaceuticals (NASDAQ:RTTR) last posted its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.14. As a group, sell-side analysts forecast that Ritter Pharmaceuticals will post -1.3 EPS for the current year.

A hedge fund recently bought a new stake in Ritter Pharmaceuticals stock. Virtu Financial LLC purchased a new position in Ritter Pharmaceuticals Inc (NASDAQ:RTTR) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 52,426 shares of the biotechnology company’s stock, valued at approximately $46,000. Virtu Financial LLC owned 0.91% of Ritter Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 6.29% of the company’s stock.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.

Featured Story: The primary rules of Elliott Wave theory

Get a free copy of the Zacks research report on Ritter Pharmaceuticals (RTTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.